英国葛兰素公司研制的中枢抗呕吐药5-HT_3拮抗剂枢复宁(ondansetron,Zofran),很有希望用于治疗焦虑及老年性记忆力障碍(AAMI)。该药对精神分裂症及成瘾性疾病的研究还未达到临床前研究所预期的效果。该公司将枢复宁用于 CNS 疾病的研究始于1988年。AAMI 临床研究显示枢复宁是第一个对记忆障碍有效的药品。随机接受枢复宁3 The British anti-emetic 5-HT_3 antagonist, ondansetron (Zofran), developed by Glaxo, is promising for the treatment of anxiety and senile memory impairment (AAMI). The drug for schizophrenia and addiction disease research has not yet reached the preclinical results expected. The company will focus on the CNS disease research began in 1988. AAMI clinical studies have shown that Pifoxef is the first drug effective for memory disorders. Randomly accept the pivot Fu Ning 3